Press and media
Press releases
More regular updates and key information, updates and news can be found through our tweets
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
CellCentric strengthens leadership team
Latest tweets from @CellCentric
Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: https://clinicaltrials.gov/study/NCT06322927 @TheChristieNHS
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: https://clinicaltrials.gov/study/NCT06322927 @TheChristieNHS
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: https://clinicaltrials.gov/study/NCT06322927 @TheChristieNHS
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.